Programme

Programme

The preliminary schedule and programme of the workshop are listed below. The programme will be updated according to the feedback from the speakers, so please watch this space.

 

Last updated: April 30, 2018

 

Wednesday 24 October, 12.00 - 13.00:

Registration and sandwich lunch

 

Wednesday 24 October, 13.00 - 18.00:

Talks

 

Wednesday 24 October, 18.00 - :

Welcome reception

 

Thursday 25 October, 8.45 - 18.00:

Talks and poster session 1

 

Friday 26 October, 9.00 - 17.30:

Talks and poster session 2

 

Friday 26 October, 19.00 - :

Conference dinner

 

 

 

Confirmed Speakers (presentation titles subject to change):

 

 

Developmental pathways implicated in the pathogenesis of germ cell malignancy

 

Walfred Tang (Cambridge, UK): Epigenetic dysregulation of primordial germ cells and gonocytes as a mechanism of transformation to germ cell neoplasia in situ.

 

Anne Jørgensen (Copenhagen, DK): The involvement of NODAL/Activin pathway in testicular dysgenesis and dysregulation of pluripotency in human fetal germ cells.

 

Rod Mitchell (Edinburgh, UK): Deregulation of human testicular development by endocrine disruptors; evidence from experimental studies. Implications for testicular cancer in humans?

 

 

 

Epidemiology and risk factors for testicular cancer

 

Jason K. Gurney (Wellington, New Zealand): Unexpected features of the epidemiology of testicular cancer among different populations in New Zealand.

 

Katherine McGlynn (Bethesda, MD, USA): Changing trends in the incidence of testicular cancer: are we close to an explanation of ethnic differences?

 

Ariana Znaor (Lyon, France): Global patterns and trends in testicular cancer incidence.

 

 

 

Genetic predisposition, genomic and epigenetic changes in testicular cancer

 

Kate Nathanson (Philadelphia, PA, USA): Novel testicular cancer predisposition loci begin to reveal possible mechanisms.

 

Maria Santa Rocca (Padua, Italy): Association between copy number variations and risk of testicular cancer.

 

Saud H. Aldubayan (Boston, MA, USA): Genomic changes during progression of testicular germ cell cancer

 

Anne Goriely (Oxford, UK): Spermatocytic tumours: what can this rare TGCT teach us about the fundamental processes operating in the adult male germline?

 

Leendert H. Looijenga (Rotterdam, the Netherlands): Clinical relevance of (epi)genetic changes during reprograming of GCNIS/seminoma to nonseminomas.

 

 

 

Paediatric germ cell tumours: New insights into the pathogenesis

 

Jason Heaney (Houston, TX, USA): Insights into malignant transformation of primordial germ cells from non-primate animal models.

 

James Amatruda (Dallas, TX, USA): Genomics of pediatric germ cell tumours.

 

Lindsay Frazier (Boston, MA, USA): Should there be a different therapeutic approach to pediatric vs. adolescent/young adult germ cell tumor patients?

 

 

 

Novel mechanisms and pathways possibly involved in germ cell cancer and male infertility

 

Ramsay J. McFarlane (Bangor, Wales, UK): Meiosis-like functions in oncogenesis.

 

Aspasia Ploubidou (Jena, Germany): Spindle misorientation in the aetiology of germ cell disorders, hypofertility and testicular germ cell cancer.

 

Robert S. Weiss (Durham NC, USA): A mouse model of malignant testicular cancer based on KRAS activation and PTEN inactivation.

 

Trine Haugen (Oslo, Norway): SPRY4 and SPRY4-IT1 as possible oncogenes in TGCT.

 

Hubert Schorle (Bonn, Germany): The plasticity of germ cell cancer and its dependence on the cellular microenvironment.

 

Joanna Selfe (London, UK): IGF1R signalling in primordial germ cells and testicular cancer.

 

 

 

Immunological aspects of testicular germ cell tumours

 

Michal Chovanec (Bratislava, Slovakia): Immune mechanisms and possible immune therapy in testicular germ cell tumours.

 

Kate Loveland (Clayton, VIC, Australia): Cytokins in testicular germ cell cancer.

 

 

 

Mechanisms and management of resistance to chemotherapy

 

Daniel Berney (London, UK): What is new in the latest WHO classification of testicular tumours and what else needs to be changed.

 

Carsten Bokemeyer (Hamburg, Germany): Clinical features and current treatment of refractory germ cell tumours.

 

Christoph Oing (Hamburg, Germany): Molecular basis of treatment resistance and potential therapeutic targets.

 

 

 

Early diagnosis and management of testicular cancer

 

Klaus-Peter Dieckmann (Hamburg, Germany): Detection of GCNIS using specific miRNA profiles.

 

Kristian Almstrup (Copenhagen, DK): Is it possible to detect GCNIS/early tumours in semen samples?

 

Gedske Daugaard (Copenhagen, DK): Risk factors predicting relapse of stage I testicular cancer undergoing surveillance.

 

Joerg Beyer (Bern, Switzerland): Risk classification in patients with disseminated disease.

 

Robert Hamilton (Toronto, Canada): Surgical treatment of disseminated GCTs – what is new and why?

 

 

 

Management of late effects in testicular cancer survivors

 

Jourik A. Gietema (Groningen, The Netherlands): Genetic susceptibility to late effects of chemotherapy in TGCT survivors.

 

Mikkel Bandak (Copenhagen, DK): Testicular function in long-term survivors of testicular cancer and the effects of androgen replacement therapy.

 

Jakob Lauritsen (Copenhagen, DK): Risk of cardio-vascular disease in long-term survivors of testicular cancer.

 

Michael Kreiberg (Copenhagen, DK): Quality of life in long-term survivors of testicular cancer.

 

 

 

 

Two poster sessions planned on Basic Aspects and Clinical Aspects (with guided tours).